Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model

Cara Usher; Lesley Tilson; Jens Olsen; Martin Jepsen; Cathal Walsh; Michael Barry

doi:10.1016/j.vaccine.2008.07.098

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model

Cara Usher, Lesley Tilson, Jens Olsen, Martin Jepsen, Cathal Walsh, Michael Barry

Research output: Contribution to journal › Article › peer-review

Abstract

We evaluated the cost-effectiveness of combining a cervical cancer screening programme with a national HPV vaccination programme compared to a screening programme alone to prevent cervical dysplasia and cervical cancer related to HPV types 16 and 18 in the Irish healthcare setting. The incremental cost effectiveness of vaccination strategies for 12-year-old females (base-case) and 12-26-year-old catch-up vaccination strategies were examined. The base-case incremental cost-effectiveness ratio was €17,383/LYG. Using a probabilistic sensitivity analysis about the base-case, the 95% CI for cost per LYG was (€3400 to €38,400). This suggests that vaccination against HPV types 16 and 18 would be cost-effective from the perspective of the Irish healthcare payer.

Original language	English
Pages (from-to)	5654-5661
Number of pages	8
Journal	Vaccine
Volume	26
Issue number	44
DOIs	https://doi.org/10.1016/j.vaccine.2008.07.098
Publication status	Published - 16 Oct 2008
Externally published	Yes

Keywords

Cost effectiveness
Decision maker
HPV vaccination

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2008.07.098

Cite this

@article{e131756b3b4342c7a2c4b1d7ddf9c7a9,

title = "Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model",

abstract = "We evaluated the cost-effectiveness of combining a cervical cancer screening programme with a national HPV vaccination programme compared to a screening programme alone to prevent cervical dysplasia and cervical cancer related to HPV types 16 and 18 in the Irish healthcare setting. The incremental cost effectiveness of vaccination strategies for 12-year-old females (base-case) and 12-26-year-old catch-up vaccination strategies were examined. The base-case incremental cost-effectiveness ratio was €17,383/LYG. Using a probabilistic sensitivity analysis about the base-case, the 95% CI for cost per LYG was (€3400 to €38,400). This suggests that vaccination against HPV types 16 and 18 would be cost-effective from the perspective of the Irish healthcare payer.",

keywords = "Cost effectiveness, Decision maker, HPV vaccination",

author = "Cara Usher and Lesley Tilson and Jens Olsen and Martin Jepsen and Cathal Walsh and Michael Barry",

year = "2008",

month = oct,

day = "16",

doi = "10.1016/j.vaccine.2008.07.098",

language = "English",

volume = "26",

pages = "5654--5661",

journal = "Vaccine",

issn = "0264-410X",

number = "44",

}

TY - JOUR

T1 - Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model

AU - Usher, Cara

AU - Tilson, Lesley

AU - Olsen, Jens

AU - Jepsen, Martin

AU - Walsh, Cathal

AU - Barry, Michael

PY - 2008/10/16

Y1 - 2008/10/16

N2 - We evaluated the cost-effectiveness of combining a cervical cancer screening programme with a national HPV vaccination programme compared to a screening programme alone to prevent cervical dysplasia and cervical cancer related to HPV types 16 and 18 in the Irish healthcare setting. The incremental cost effectiveness of vaccination strategies for 12-year-old females (base-case) and 12-26-year-old catch-up vaccination strategies were examined. The base-case incremental cost-effectiveness ratio was €17,383/LYG. Using a probabilistic sensitivity analysis about the base-case, the 95% CI for cost per LYG was (€3400 to €38,400). This suggests that vaccination against HPV types 16 and 18 would be cost-effective from the perspective of the Irish healthcare payer.

AB - We evaluated the cost-effectiveness of combining a cervical cancer screening programme with a national HPV vaccination programme compared to a screening programme alone to prevent cervical dysplasia and cervical cancer related to HPV types 16 and 18 in the Irish healthcare setting. The incremental cost effectiveness of vaccination strategies for 12-year-old females (base-case) and 12-26-year-old catch-up vaccination strategies were examined. The base-case incremental cost-effectiveness ratio was €17,383/LYG. Using a probabilistic sensitivity analysis about the base-case, the 95% CI for cost per LYG was (€3400 to €38,400). This suggests that vaccination against HPV types 16 and 18 would be cost-effective from the perspective of the Irish healthcare payer.

KW - Cost effectiveness

KW - Decision maker

KW - HPV vaccination

UR - http://www.scopus.com/inward/record.url?scp=52949147772&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.07.098

DO - 10.1016/j.vaccine.2008.07.098

M3 - Article

C2 - 18723068

AN - SCOPUS:52949147772

SN - 0264-410X

VL - 26

SP - 5654

EP - 5661

JO - Vaccine

JF - Vaccine

IS - 44

ER -

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this